VivoSeq
Infectious Disease

Influenza, Human+covid-19

2

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Influenza, Human+COVID-19 is an early-stage landscape with 2 programs across 1 company. The most active players are GSK.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

3 programs

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Licensed Seasonal Influenza Vaccine

GSK

Licensed COVID-19 Vaccine

GSK

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
Recruiting·GSK logoGSK·Phase 1·NCT07464314·225 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)